Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease

Neurobiology of Disease

Volumn 45, Issue 1, 2012, Pages 438-449

  Franciosi, Sonia ^a   Ryu, Jae K ^b   Shim, Yaein ^a   Hill, Austin ^a   Connolly, Colum ^a   Hayden, Michael R ^a   McLarnon, James G ^b   Leavitt, Blair R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blood brain barrier; Cytokine; Huntington disease; Inflammation; Microglia; Neurovasculature; Striatum; YAC128

Indexed keywords

ENDOTOXIN; LIPOPOLYSACCHARIDE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CELL ACTIVATION; CELL AGING; CELL SIZE; CELL STRUCTURE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; COORDINATION DISORDER; CORPUS STRIATUM; DISEASE MODEL; GLIOSIS; HUNTINGTON CHOREA; MICROGLIA; MICROGLIOSIS; MOUSE; MOUSE STRAIN; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; YAC128 MOUSE;

AGE FACTORS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL SHAPE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MICROGLIA; PHENOTYPE;

EID: 81955167911     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.09.003     Document Type: Article

References (48)

1. Andre C., O'Connor J.C., Kelley K.W., Lestage J., Dantzer R., Castanon N. Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2.3-dioxygenase in response to peripheral lipopolysaccharide administration. J. Neuroimmunol. 2008, 200:90-99.
2. Bailey T.L., Rivara C.B., Rocher A.B., Hof P.R. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol. Res. 2004, 26:573-578.
3. Banks W.A., Robinson S.M. Minimal penetration of lipopolysaccharide across the murine blood-brain barrier. Brain Behav. Immun. 2010, 24:102-109.
4. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M.A., Hayden M.R., Khalili-Shirazi A., Lowdell M.W., Brundin P., Bates G.P., Leavitt B.R., Moller T., Tabrizi S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
5. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide induced sickness behavior: a study with interleukin-1 type 1 receptor-deficient mice. Eur. J. Neurosci. 2000, 12:4447-4456.
6. Bluthe R.M., Michaud B., Poli V., Dantzer R. Role of IL-6 in cytokine induced sickness behavior: a study with IL-6 deficient mice. Physiol. Behav. 2000, 70:367-373.
7. Calhoun M.E., Mouton P.R. Length measurement: new developments in neurostereology and 3D imagery. J. Chem. Neuroanat. 2001, 21:257-265.
8. Chung D.W., Yoo K.Y., Hwang I.K., Kim D.W., Chung J.Y., Lee C.H., Choi J.H., Choi S.Y., Youn H.Y., Lee I.S., Won M.H. Systemic administration of lipopolysaccharide induces cyclooxygenase-2 immunoreactivity in endothelium and increases microglia in mouse hippocampus. Cell. Mol. Neurobiol. 2010, 30:531-541.
9. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neurosci 2002, 112:7-11.
10. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005, 25:9275-9284.
11. Del Zoppo G.J. Microvascular responses to cerebral ischemia/inflammation. Ann. N. Y. Acad. Sci. 1997, 823:132-147.
12. Duran-Vilaregut J, Del Valle J, Manich G, Camins A, Pallàs M, Vilaplana J, Pelegrí C. Role of MMP-9 in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease. Neuropathol Appl Neurobiol Accepted manuscript online: 22 DEC 2010.
13. Farkas E., De Jong G.I., de Vos R.A., Jansen Steur E.N., Luiten P.G. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (Berl) 2000, 100:395-402.
14. Franciosi S., De Gasperi R., Dickstein D.L., English D.F., Rocher A.B., Janssen W.G., Christoffel D., Sosa M.A., Hof P.R., Buxbaum J.D., Elder G.A. Pepsin pretreatment allows collagen IV immunostaining of blood vessels in adult mouse brain. J. Neurosci. Methods 2007, 163:76-82.
15. Gaillard P.J., de Boer A.B., Breimer D.D. Pharmacological investigations on lipopolysaccharide-induced permeability changes in the blood-brain barrier in vitro. Microvasc. Res. 2003, 65:24-31.
16. Godbout J.P., Chen J., Abraham J., Richwine A.F., Berg B.M., Kelley K.W., Johnson R.W. Exaggerated neuroinflammation and sickness behaviour in aged mice following activation of the peripheral innate immune system. FASEB J. 2005, 19:1329-1331.
17. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
18. Harris G.J., Aylward E.H., Peyser C.E., Pearlson G.D., Brandt J., Roberts-Twillie J.V., Barta P.E., Folstein S.E. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch. Neurol. 1996, 53:316-324.
19. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122:1667-1678.
20. Holmes C., Cunningham C., Zotova E., Woolford J., Dean C., Kerr S., Culliford D., Perry V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurol 2009, 73:768-774.
21. Jantaratnotai N., Schwab C., Ryu J.K., McGeer P.L., McLarnon J.G. Converging perturbed microvasculature and microglial clusters characterize Alzheimer disease brain. Curr. Alzheimer Res. 2010, 7:625-636.
22. Kalaria R.N., Pax A.B. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 1995, 705:349-352.
23. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
24. Kreczmanski P., Schmidt-Kastner R., Heinsen H., Steinbusch H.W., Hof P.R., Schmitz C. Stereological studies of capillary length density in the frontal cortex of schizophrenics. Acta Neuropathol (Berl) 2005, 109:510-518.
25. Moller T. Neuroinflammation in Huntington's disease. J. Neural Transm. 2010, 117:1001-1008.
26. Niatsetskaya Z., Basso M., Speer R.E., McConoughey S.J., Coppola G., Ma T.C., Ratan R.R. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid. Redox Signal. 2010, 12:435-443.
27. Nguyen M.D., D'Aigle T., Gowing G., Julien J.P., Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004, 24:1340-1349.
28. Pan W., Kastin A.J. Adipokines and the blood-brain barrier. Peptides 2007, 28:1317-1330.
29. Paul J., Strickland S., Melchor J.P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 2007, 204:1999-2008.
30. Pavese N., Gerhard A., Tai Y.F., Ho A.K., Turkheimer F., Barker R.A., Brooks D.J., Piccini P. Microglial activation correlates with severity in Huntington disease-a clinical and PET study. Neurol 2006, 66:1638-1643.
31. Perry V.H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010, 120:277-286.
32. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
33. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
34. Ryu J.K., McLarnon J.G. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J. Cell. Mol. Med. 2009, 13:2911-2925.
35. Sala G., Galimberti G., Canevari C., Raggi M.E., Isella V., Facheris M., Appollonio I., Ferrarese C. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol. Aging 2003, 24:909-914.
36. Sapp E., Kegel K.B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P.G., Vonsattel J.P., DiFiglia M. Early and progressive accumulation of reactive microglia in the Huntington's disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
37. Silvestroni A., Faull R.L.M., Strand A.D., Moller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
38. Singh A.K., Yiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats?. Toxicology 2004, 201:197-207.
39. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuron loss in YAC128 mouse model of Huntington's disease. Hum. Mol. Genet. 2003, 12:1555-1567.
40. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 2001, 56:581-588.
41. Squitieri F., Cannella M., Simonelli M., Sassone J., Martino T., Venditti E., Ciammola A., Colonnese C., Frati L., Ciarmiello A. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci. Ther. 2009, 15:1-11.
42. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
43. Van Gool W.A., van de Beek D., Eikelenboom P. Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 2010, 375:773-775.
44. Verma S., Nakaoke R., Dohgu S., Banks W.A. Release of cytokines by brain endothelial cells: a polarized response to lipopolysaccharide. Brain Behav. Immun. 2006, 20:449-455.
45. Vis J.C., Nicholson L.F.B., Faull R.L.M., Evans W.H., Severs N.J., Green C.R. Connexin expression in Huntington's diseased human brain. Cell Biol. Int. 1998, 22:837-847.
46. Xaio H., Banks W.A., Niehoff M.L., Morley J.E. Effect of LPS on the permeability of the blood-brain barrier to insulin. Brain Res. 2001, 896:36-42.
47. Zacchigna S., Lambrechts D., Carmeliet P. Neurovascular signaling defects in neurodegeneration. Nature Rev Neurosci 2008, 9:169-181.
48. Ziegler-Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J. Inflamm. 1995, 45:13-26.